KOBAYASHI PHARM
There is no Profile data available for KOY.MU.
KOBAYASHI PHARM (KOY) - Total Liabilities
Latest total liabilities as of June 2025: €52.47 Billion EUR
Based on the latest financial reports, KOBAYASHI PHARM (KOY) has total liabilities worth €52.47 Billion EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
KOBAYASHI PHARM - Total Liabilities Trend (2017–2024)
This chart illustrates how KOBAYASHI PHARM's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
KOBAYASHI PHARM Competitors by Total Liabilities
The table below lists competitors of KOBAYASHI PHARM ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AB Utenos Trikotazas
MU:UD5
|
Germany | €12.06 Million |
|
TAKEDA PHARMA - Dusseldorf Stock Exchang
DU:TKD
|
Germany | €7.65 Trillion |
|
SANRIO
MU:SJ8
|
Germany | €69.58 Billion |
|
Guess? Inc.
NYSE:GES
|
USA | $2.44 Billion |
|
Gold Flora Corp
PINK:GRAMW
|
USA | $273.12 Million |
|
SEAWLD ENT
MU:W2L
|
Germany | €3.04 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down KOBAYASHI PHARM's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how KOBAYASHI PHARM's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for KOBAYASHI PHARM (2017–2024)
The table below shows the annual total liabilities of KOBAYASHI PHARM from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €51.90 Billion | -17.17% |
| 2023-12-31 | €62.66 Billion | +8.16% |
| 2022-12-31 | €57.93 Billion | +1.71% |
| 2021-12-31 | €56.95 Billion | +2.10% |
| 2020-12-31 | €55.78 Billion | -8.16% |
| 2019-12-31 | €60.74 Billion | -6.18% |
| 2018-12-31 | €64.74 Billion | -0.43% |
| 2017-12-31 | €65.02 Billion | -- |